XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone. 

It will be a while while the FDA and EU regulatory agencies decide if Xtandi could be sold for us by nmCRPC patients.   Malecare will keep you up to date.

“In patients with non-metastatic CRPC, there is a high unmet need to delay developm